Heavy Alcohol Use With Prior Withdrawal Seizure
Mr. L, 41, self-refers after an emergency department visit for palpitations. He reports drinking 12–16 standard drinks daily for 8 months; his last drink was 18 hours ago. He has a history of a withdrawal seizure 3 years ago and is now tremulous and diaphoretic, with BP 158/96, HR 112, and CIWA-Ar 14. He also meets criteria for severe cannabis use disorder, using daily. He reports 3 weeks of anhedonia and insomnia that began before his heaviest drinking but worsened after a job loss. He lives alone, has no reliable transport, and his employer requires treatment documentation. He denies suicidal ideation but says he 'would not mind not waking up.' Urine is positive for cannabis and alcohol; no other substances. He asks whether he can taper at home because he cannot afford time off.
1. What are the immediate assessment and withdrawal-management priorities, and what level of care is indicated? Justify the decision using the clinical details.
Read the worked answer
The prior withdrawal seizure, current CIWA-Ar score, autonomic instability, and daily heavy drinking put Mr. L at high risk for complicated withdrawal. He needs medically supervised withdrawal, not a self-taper.
I would arrange urgent medical evaluation with withdrawal monitoring, likely at ASAM Level 3.2-D or 3.7 depending on vital-sign stability, electrolyte status, and staffing. A stand-alone outpatient program is not adequate here. Priorities include seizure precautions, serial CIWA-Ar, thiamine before glucose, electrolytes, liver function, and medication-assisted withdrawal per protocol. Cannabis withdrawal is uncomfortable but not medically dangerous.
I would also screen suicide risk now and again after withdrawal because of his passive death wish. The employer letter should disclose only the minimum necessary information and only with a signed release. Diagnosis is provisional: alcohol withdrawal and severe alcohol and cannabis use disorders; mood symptoms should be reassessed after withdrawal rather than diagnosed definitively during intoxication or early abstinence.
2. How would you distinguish a substance-induced depressive disorder from an independent major depressive disorder, and how does that change the treatment plan?
Read the worked answer
I would look at timing and course: whether anhedonia and insomnia clearly began before heavy drinking, whether similar episodes occurred during past abstinence, whether there is a family or personal history of independent depression, and whether symptoms persist after withdrawal. DSM-5-TR substance-induced depressive disorder requires symptoms attributable to substance use and not better explained by an independent disorder; persistence beyond the expected withdrawal period is a key clue.
Because he is still drinking heavily and is early in withdrawal, I would not start an antidepressant based only on today's symptoms. I would stabilize withdrawal, treat the substance use disorders, monitor mood with a validated measure, and reassess in 2–4 weeks. If depression persists or there is a clear independent history, I would integrate depression treatment with SUD treatment rather than treating either condition in isolation. If suicidal risk worsens, safety planning and higher-level care take priority over diagnostic certainty.
3. What additional information would you gather before finalizing the diagnosis and level of care?
Read the worked answer
I would complete the ASAM dimensions rather than relying on the CIWA-Ar alone: past detoxifications and seizures, medical history, current medications, liver function, nutrition, trauma history, psychiatric history, suicide risk, social support, transportation, housing, and ability to attend daily treatment. I would ask about blackouts, falls, pancreatitis, hypertension, and prior hospitalizations.
Collateral information, with consent, could clarify the timeline of mood symptoms and drinking. I would also ask about cannabis use patterns and consequences, not just the positive urine screen. The level of care should match withdrawal risk, biomedical stability, psychiatric safety, relapse potential, and recovery environment. His lack of transport and inability to take time off are practical barriers, but they do not justify an unsafe home taper.